PLCL1, as a survival-related gene of GC, is also significantly correlated with clinical characteristics, tumor microenvironment immune cells, tumor mutation burden (TMB), and tumor necrosis factor (TNF) (33). This evidence concerns the gene TNF and neoplasm.